Genmab — August 2020
-
Summary points from expert feedback:
Uptake of Kesimpta will be brisk as it is a known mechanism and modality
Kesimpta’s monthly convenience will drain market share from older injectables
No clear difference on safety/efficacy for anti-CD20 mAbs like Kesimpta and Roche’s Ocrevus -
-
Tak Sukker.
-
Hvis Kesimpta kan dele markedet for nye patienter 50/50 med Ocrevus, så er det bedre end hvad der tidligere er estimeret. Vil være rigtig godt
-
Snakken om aktiesplit har været lidt stille det sidste lange stykke tid. Sidst var der ikke overbevisende stemning for det her på siden, men hvordan er sentiment nu? Apple og Tesla er gode eksempler på, at det kan betyde meget for psykologien om en aktie, når den bliver peberet. Tanker?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind